Table 2.
Morpho-immunohistologic findings in breast cancer molecular classes
| LUMA (n=113) | LUMB (n=31)§ | TN (n=32) | ERBB2 (n=8) | LAHH (n=10) | LBHH (n=8) | |
|---|---|---|---|---|---|---|
| Nottingham Grade: | ||||||
| I | 41 (37%) | 10 (32%) | 0 (0%) | 0 (0%) | 1 (10%) | 1 (12%) |
| II | 58 (52%) | 17 (55%) | 6 (19%) | 3 (38%) | 6 (60%) | 4 (50%) |
| III | 14 (11%) | 4 (13%) | 26 (81%) | 5 (62%) | 3 (30%) | 3 (38%) |
| Necrosis: | ||||||
| Absent | 113(100%) | 30 (97%) | 24(75%) | 5 (62%) | 10(100%) | 8(100%) |
| Present | 0 (0%) | 1 (3%) | 8 (25%) | 3 (38%) | 0 (0%) | 0 (0%) |
| Lymphoid | ||||||
| Infiltrate: | 66 (58%) | 16 (52%) | 4 (13%) | 0 (0%) | 4 (40%) | 3 (38%) |
| None | 39 (35%) | 14 (45%) | 10 (31%) | 3 (38%) | 6 (60%) | 5 (62%) |
| Mild | 6 (5%) | 1 (3%) | 15 (47%) | 5 (62%) | 0 (0%) | 0 (0%) |
| Moderate | 2 (2%) | 0 (0%) | 3 (9%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Marked | ||||||
| Borders: | ||||||
| Infiltrating | 101 (89%) | 27 (87%) | 24 (75%) | 8 (100%) | 10(100%) | 8 (100%) |
| Pushing | 12 (11%) | 4 (13%) | 8 (25%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Apocrine | ||||||
| Differentiation: | 109 (96%) | 29 (94%) | 23 (72%) | 1 (13%) | 8 (80%) | 6 (75%) |
| Absent | 4 (4%) | 2 (6%) | 9 (28%) | 7 (87%) | 2 (20%) | 2 (25%) |
| Present | ||||||
| Nucleoli: | ||||||
| Not prominent | 109 (96%) | 27 (87%) | 23 (72%) | 4 (50%) | 8 (80%) | 7 (87%) |
| Prominent | 4 (4%) | 4 (13%) | 9 (28%) | 4 (50%) | 2 (20%) | 1 (13%) |
| Nodal Status*: | ||||||
| Negative | 74 (70%) | 12 (50%) | 21 (78%) | 5 (71%) | 7 (70%) | 2 (40%) |
| Positive | 31 (30%) | 12 (50%) | 6 (22%) | 2 (29%) | 3 (30%) | 3 (60%) |
| Tumor Size: | ||||||
| Mean (cm) | 1.56 | 1.62 | 2.14 | 1.6 | 1.5 | 2.3 |
| Median (cm) | 1.5 | 1.4 | 1.5 | 1.2 | 1.3 | 1.9 |
| Range (cm) | 0.6–4.5 | 0.5–3.5 | 0.8–7 | 0.6–2.5 | 0.8–3.2 | 1–6.5 |
| Patient Age: | ||||||
| Mean (yrs) | 62 | 55 | 57 | 64 | 56 | 57 |
| Median (yrs) | 62 | 50 | 54 | 65 | 56 | 49 |
| Range (yrs) | 41–90 | 40–81 | 39–90 | 51–86 | 37–73 | 43–83 |
| ER Score: | NA | NA | ||||
| Mean | 261 | 172 | 242 | 156 | ||
| Median | 270 | 180 | 245 | 175 | ||
| Range | 200–300 | 90–195 | 200–290 | 60–190 | ||
| PR Score: | NA | NA | ||||
| Mean | 147 | 108 | 143 | 75 | ||
| Median | 150 | 101 | 150 | 53 | ||
| Range | 0–295 | 0–245 | 6–300 | 0–200 | ||
| Ki-67 LI: | ||||||
| Mean (%) | 15.8 | 15.9 | 61.7 | 27.8 | 16.3 | 24.6 |
| Median (%) | 11 | 12 | 66 | 31 | 14 | 29 |
| Range (%) | 1–73 | 1–60 | 9–94 | 10–41 | 1–40 | 11–36 |
| CK5*: | ||||||
| Negative | 107(100%) | 25 (93%) | 9 (29%) | 3 (38%) | 10(100%) | 8 (100%) |
| Positive | 0 (0%) | 2 (7%) | 22 (71%) | 5 (62%) | 0 (0%) | 0 (0%) |
NA, Not Applicable.
*
Data not available on all cases.
§
Three LUMB tumors showing sheet like growth pattern similar to “basal-like” carcinoma were excluded from the analysis.